Universal Cells creates Universal Donor Stem Cells by editing the genes required for immune recognition. By using our recombinant Adeno-Associated Virus (rAAV) technology, we design and manufacture stem cell-based products that can be used as off-the-shelf cell therapies.
Universal Donor Cells are pluripotent and can differentiate into various cell types that can be used to treat a vast number of diseases. Learn more about the Universal Cells’ pipeline and partnerships.
Seattle, WA – May 15th, 2017 – Universal Cells announced today that a report from Universal Cells’ CSO Dr. David Russell and researchers at the University of Washington demonstrating the potential of Universal [...]
Seattle, WA – Universal Cells announced today that Claudia Mitchell, CEO will present at the Alliance for Regenerative Medicine’s 5th Annual Cell & Gene Therapy Investor Day on Thursday, April 27, 2017 at [...]
Seattle, WA – Universal Cells Inc. (http://www.universalcells.com) has announced that Dr. Bryan Steadman has joined the company as Chief Technology Officer. He is responsible for the translation of R&D to GMP activities and leadership of [...]